Manufacturer price change requests

Price change process for generic drugs

The pan-Canadian Pharmaceutical Alliance (pCPA) has a centralized price change process and submissions for generic molecules must be made directly to the pCPA.

Manufacturers can submit a single completed request form to the pCPA rather than submitting to each participating drug plan.

For questions regarding generic submissions, contact the pCPA generics team.

Price change process for brand products

Manufacturers may submit price change requests for brand products by completing this request form (XLSX) and emailing it to ns.pharmacare.price.list@medavie.bluecross.ca and pharm.pricing@novascotia.ca.

Additional information

Requests for price increases to be considered for implementation on 1 April 2027 must be received by 31 December 2026.

Incomplete submissions or submissions received after the deadline will not be considered.

Submission of a request does not guarantee approval. All requests are reviewed by Nova Scotia, and manufacturers will be contacted directly regarding the review outcome.

When reviewing price increase requests, the province may consider factors such as the Consumer Price Index (CPI), pan-Canadian pricing, previously approved price increases, product supply, therapeutic class, utilization, availability of competitors, budget impact and other relevant factors.

The province reserves the right to modify the methodology used for annual price reviews.

Manufacturers may request price decreases at any time, provided sufficient notice is given to allow for publication and system updates.

Manufacturers are responsible for ensuring approved price changes are implemented through their wholesale and distribution networks. Nova Scotia reimburses based on the approved list price rather than the wholesale acquisition cost.